Highlights Newsletter 3
This newsletter presents you the following key sessions:
1. Podcast with Prof. Gertjan Kaspers about the use of MRD-based risk stratification in the NOPHO-DBH AML 2012
protocol for the treatment of paediatric AML patients
2. Adding isatuximab to carfilzomib, lenalidomide, and dexamethasone (KRd) significantly increases minimal
residual disease negativity rates in patients with NDMM
3. Crizanlizumab fails to demonstrate benefit over placebo in patients with sickle cell disease
4. Auto-HCT outperforms CAR-T therapy in patients with large B-Cell lymphoma achieving complete remission after
chemotherapy